Dassault Systèmes Successfully Completes Tender Offer for Accelrys
Article Apr 30, 2014
Dassault Systèmes, the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions has announced the completion of the tender offer by its wholly owned indirect subsidiary, 3DS Acquisition Corp., to purchase all of the outstanding shares of Accelrys, Inc. common stock at an offer price of $12.50 per share in cash, without interest and subject to any required withholding of taxes. The tender offer expired at midnight, New York City time, at the end of the day on April 28, 2014.
Computershare Trust Company, N.A., the depositary for the tender offer, has advised that as of the expiration of the tender offer, 44,834,627 shares of Accelrys common stock had been validly tendered and not validly withdrawn pursuant to the tender offer, representing approximately 80.2 percent of the outstanding shares of Accelrys common stock. In addition, Notices of Guaranteed Delivery were delivered for 548,670 shares of Accelrys common stock, representing approximately 1.0 percent of the outstanding shares of Accelrys common stock. The condition to the tender offer that a majority of Accelrys’ outstanding shares on a fully diluted basis (excluding shares delivered pursuant to Notices of Guaranteed Delivery) be validly tendered and not validly withdrawn and all other conditions to the tender offer have been satisfied. Accordingly, 3DS Acquisition Corp. has accepted for payment and will promptly pay the depositary for all validly tendered shares.
Dassault Systèmes expects to complete the acquisition of Accelrys through a merger under Section 251(h) of the General Corporation Law of the State of Delaware. Subject to perfected appraisal rights, all remaining shares of Accelrys common stock not tendered into the tender offer and not owned by Accelrys, 3DS Acquisition Corp. or Dassault Systèmes Americas Corp. will be canceled in the merger and converted into the right to receive $12.50 per share in cash, without interest and subject to any required withholding of taxes, which is the same price that was paid in the tender offer. Following completion of the merger, shares of Accelrys common stock will no longer be listed on the NASDAQ Global Select Market.
Untargeted metabolomics approaches are allowing previously unreported insights into the pathogenesis of disease. However, identifying the large numbers of unknown and structurally diverse metabolites typically present in biological samples has proven to be a major bottleneck. Fortunately, recent advances in technology and software are helping to overcome this challenge.READ MORE
The UK’s national health system needs to take a hard look at their priorities and procedures to ensure that rapid advances in molecular diagnostics in lung cancer are translated into a practical service for all patients, according to a report launched at the British Thoracic Oncology Group Annual Conference.READ MORE
First developed in the 1970s, recent developments are making microflow liquid chromatography techniques more robust – enticing researchers to revisit the opportunities it offers for more sensitive, high-throughput analyses requiring smaller sample volumes than standard flow techniques.READ MORE
2nd World Congress on Healthcare and Hospital Management
Aug 19 - Aug 20, 2019